BNB Plus Earnings Call Transcripts
Fiscal Year 2026
-
Stockholders approved granting the board authority for a reverse stock split at a ratio between 1-for-5 and 1-for-30, and also approved the adjournment proposal. Both measures passed with a majority of votes, and final results will be filed with the SEC.
-
BNBX leverages four non-directional yield strategies on BNB to target 9%-12% annualized returns, combining long BNB exposure with compounding yield. The approach offers a unique way to access Binance’s growth and earnings, with robust risk management and operational transparency.
-
BNB Plus outlined its BNB-focused digital asset treasury strategy, leveraging unique yield opportunities and deflationary tokenomics to target 8%-12% annualized returns. The company has restructured its legacy DNA business for profitability and is exploring M&A to scale.
Fiscal Year 2025
-
Restructuring shifted focus to LineaRx and synthetic DNA, exiting DNA tagging and reducing workforce. Q1 revenue rose to $1.2M, with improved operating loss and strong cash reserves. GMP facility launch, new product introductions, and robust sales pipeline position the company for growth in 2025.
Fiscal Year 2024
-
Transitioning to a pure-play biotech, the company is launching a GMP facility focused on linear DNA and RNA technologies that dramatically reduce production times and improve quality for genetic medicines. Proprietary platforms and enzymes position it for growth in personalized therapies and recurring revenue as adoption increases.
-
Q3 2024 saw revenues drop sharply due to the end of COVID-19 testing, with gross margin and adjusted EBITDA declining. Management expects a revenue inflection in early fiscal 2025, driven by new biotherapeutic and DNA tagging contracts, while maintaining a strengthened cash position from recent financing.